Gilead Sciences EBITDA vs. Current Liabilities

GILD Stock  USD 66.93  0.38  0.56%   
Based on Gilead Sciences' profitability indicators, Gilead Sciences is performing exceptionally good at this time. It has a great odds to showcase excellent profitability results in May. Profitability indicators assess Gilead Sciences' ability to earn profits and add value for shareholders.
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
7.6 B
Current Value
4.9 B
Quarterly Volatility
6.1 B
 
Credit Downgrade
 
Yuan Drop
 
Covid
At present, Gilead Sciences' Operating Cash Flow Sales Ratio is projected to increase slightly based on the last few years of reporting. At present, Gilead Sciences' Net Income From Continuing Ops is projected to decrease significantly based on the last few years of reporting. The current year's Change To Netincome is expected to grow to about 4.2 B, whereas Income Before Tax is forecasted to decline to about 4.2 B.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin1.070.7799
Significantly Up
Pretty Stable
For Gilead Sciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Gilead Sciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Gilead Sciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Gilead Sciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Gilead Sciences over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis.
For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.
Is Gilead Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.13)
Dividend Share
3
Earnings Share
4.5
Revenue Per Share
21.728
Quarterly Revenue Growth
(0.04)
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Gilead Sciences Current Liabilities vs. EBITDA Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Gilead Sciences's current stock value. Our valuation model uses many indicators to compare Gilead Sciences value to that of its competitors to determine the firm's financial worth.
Gilead Sciences is one of the top stocks in ebitda category among related companies. It is one of the top stocks in current liabilities category among related companies creating about  0.01  of Current Liabilities per EBITDA. The ratio of EBITDA to Current Liabilities for Gilead Sciences is roughly  72.50 . At present, Gilead Sciences' EBITDA is projected to increase significantly based on the last few years of reporting.Comparative valuation analysis is a catch-all model that can be used if you cannot value Gilead Sciences by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Gilead Sciences' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Gilead Sciences' earnings, one of the primary drivers of an investment's value.

Gilead Current Liabilities vs. EBITDA

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Gilead Sciences

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
7.61 B
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.

Gilead Sciences

Current Liabilities

 = 

Payables

+

Accrued Debt

 = 
104.89 M
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.

Gilead Sciences Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Gilead Sciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Gilead Sciences will eventually generate negative long term returns. The profitability progress is the general direction of Gilead Sciences' change in net profit over the period of time. It can combine multiple indicators of Gilead Sciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income28 M37.6 M
Operating Income7.6 B4.4 B
Income Before Tax6.9 B4.2 B
Total Other Income Expense Net-746 M-708.7 M
Net Income5.6 BB
Income Tax Expense-1.2 B-1.2 B
Net Income Applicable To Common Shares5.3 B4.9 B
Net Income From Continuing Ops5.8 B6.6 B
Non Operating Income Net Other-522.9 M-496.8 M
Interest Income204.3 M194.1 M
Net Interest Income-918 M-963.9 M
Change To NetincomeB4.2 B
Net Income Per Share 4.54  4.77 
Income Quality 1.43  1.36 
Net Income Per E B T 0.83  0.94 

Gilead Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Gilead Sciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Gilead Sciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Gilead Sciences' important profitability drivers and their relationship over time.

Use Gilead Sciences in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Gilead Sciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Gilead Sciences will appreciate offsetting losses from the drop in the long position's value.

Gilead Sciences Pair Trading

Gilead Sciences Pair Trading Analysis

The ability to find closely correlated positions to Gilead Sciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Gilead Sciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Gilead Sciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Gilead Sciences to buy it.
The correlation of Gilead Sciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Gilead Sciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Gilead Sciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Gilead Sciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Gilead Sciences position

In addition to having Gilead Sciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Soft Drinks Thematic Idea Now

Soft Drinks
Soft Drinks Theme
Entities manufacturing and distributing non alcoholic beverages across different markets. The Soft Drinks theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Soft Drinks Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:
Check out Risk vs Return Analysis.
For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for Gilead Stock analysis

When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
To fully project Gilead Sciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Gilead Sciences at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Gilead Sciences' income statement, its balance sheet, and the statement of cash flows.
Potential Gilead Sciences investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Gilead Sciences investors may work on each financial statement separately, they are all related. The changes in Gilead Sciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Gilead Sciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.